Get the Stockscreener App
545.46
1.64%
-9.12
After Hours:
550.00
4.54
+0.83%
Regeneron Pharmaceuticals Inc stock is traded at $545.46, with a volume of 1.41M.
It is down -1.64% in the last 24 hours and up +3.90% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$554.58
Open:
$550.01
24h Volume:
1.41M
Relative Volume:
1.12
Market Cap:
$57.90B
Revenue:
$14.09B
Net Income/Loss:
$4.50B
P/E Ratio:
13.89
EPS:
39.28
Net Cash Flow:
$2.96B
1W Performance:
-3.40%
1M Performance:
+3.90%
6M Performance:
-18.95%
1Y Performance:
-49.46%
1-Day Range:
$541.61
$558.13
1-Week Range:
$541.61
$567.95
52-Week Range:
$476.49
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Regeneron Pharmaceuticals Stock (REGN) Opinions on Upcoming Earnings Report - Quiver Quantitative
FDA Issued Myeloma, Alzheimer’s Approvals in July but Rejected Two CGTs - BioSpace
Regeneron stock price target maintained at $678 by Cantor Fitzgerald - Investing.com Canada
Seizert Capital Partners LLC Purchases 28,368 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Mackenzie Financial Corp Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Mediolanum International Funds Ltd Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Applied Finance Capital Management LLC Sells 8,524 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
ARK Investment Management LLC Acquires 502 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Sanofi raises annual sales growth expectations on strong Dupixent demand - Reuters
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Lessened by TD Asset Management Inc - MarketBeat
Regeneron (REGN) Q2 Earnings: What To Expect - Barchart.com
Canaccord Reiterates a Buy Rating on Regeneron Pharmaceuticals (REGN) - MSN
Phoenix Financial Ltd. Lowers Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron and Intellia’s Phase 3 Study on NTLA-2001: A Potential Game-Changer for ATTRv-PN - TipRanks
Regeneron and Intellia’s Promising Phase 3 Study on NTLA-2001 for ATTR-CM - TipRanks
AE Wealth Management LLC Purchases 445 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Nikko Asset Management Americas Inc. Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Zurcher Kantonalbank Zurich Cantonalbank Sells 42,590 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
First Circuit Decision Regarding Anti-Kickback Statute Standard Widens Circuit Split and Creates Potential for Supreme Court Clarification - JD Supra
Pinnacle Wealth Management Advisory Group LLC Acquires 487 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Unlocking Q2 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Pacer Advisors Inc. - MarketBeat
Regeneron Pharmaceuticals (REGN) Expected to Announce Earnings on Friday - MarketBeat
John G Ullman & Associates Inc. Acquires 3,115 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
When is Regeneron Pharmaceuticals Inc. stock expected to show significant growthMarket Forecast Outlook With Proven Results - jammulinksnews.com
What makes Regeneron Pharmaceuticals Inc. stock price move sharplyInvestment Strategy With Predictable Gains Outlined - metal.it
1,697 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by Bellwether Advisors LLC - MarketBeat
Regeneron Feels The Pressure As Eye Drug Sales Slide - Finimize
Is Regeneron Pharmaceuticals Inc. a growth stock or a value stockFree Stock Market Trend Analysis - jammulinksnews.com
IFP Advisors Inc Grows Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Assetmark Inc. Boosts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Is Regeneron Pharmaceuticals Inc. stock overvalued or undervaluedInvest smarter with actionable market insights - jammulinksnews.com
What catalysts could drive Regeneron Pharmaceuticals Inc. stock higher in 2025Achieve breakthrough investment performance - jammulinksnews.com
What are the technical indicators suggesting about Regeneron Pharmaceuticals Inc.Build wealth with long-term growth strategies - jammulinksnews.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is Legato Capital Management LLC's 9th Largest Position - MarketBeat
Rep. Robert Bresnahan, Jr. Buys Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock - MarketBeat
Pinnacle Associates Ltd. Increases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN) Acquires 23andMe Assets in $256M Deal - MSN
Regeneron Pharmaceuticals Earnings Preview: What to Expect - MSN
Canaccord Genuity Group Reiterates Buy Rating for Regeneron Pharmaceuticals (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (REGN): Can Dupixent's Growth Offset Eylea Erosion and Drive Long-Term Earnings Resilience? - AInvest
10 Most Profitable Biotech Stocks to Invest in Now - Insider Monkey
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Y Intercept Hong Kong Ltd - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Cuts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Bank of America Securities Reiterated a Sell rating on Regeneron Pharmaceuticals (REGN), Lowered the PT - Insider Monkey
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
15.43%
2.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):